Evidence mapPaperPMID 41890658Full record

ReviewInternational journal of nanomedicine2026

Multifunctional Nanoparticles in Traumatic Brain Injury: From Targeted Imaging and Diagnosis to Innovative Therapeutics.

Nouran Alwisi, Sarah Aqel, Janatul Naeim, Dana Abdulla Al-Hashimi, Samer El Hayek, Firas Kobeissy, Abdullah A Shaito

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Nanozyme-based therapeutic strategies for traumatic brain injury.International journal of pharmaceutics: X · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nouran AlwisiCollege of Medicine, QU Health, Qatar University, Doha, Qatar.ORCID 0009-0007-2785-9914
Sarah AqelQatar Biomedical Research Institute, Hamad Bin Khalifa University, Doha, Qatar.ORCID 0009-0003-4590-509X
Janatul NaeimCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Dana Abdulla Al-HashimiCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Samer El HayekAmerican Center for Psychiatry and Neurology, Dubai, United Arab Emirates.ORCID 0000-0002-7975-6104
Firas KobeissyCenter for Neurotrauma, Multiomics & Biomarkers, Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-5008-6944
Abdullah A ShaitoCollege of Medicine, QU Health, Qatar University, Doha, Qatar.ORCID 0000-0003-3524-7962

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traumatic brain injury (TBI) remains a leading cause of morbidity and mortality worldwide, with limited therapeutic progress due to challenges such as impermeability of the blood-brain barrier (BBB) and the multifactorial nature of secondary neurodegeneration. Nanoparticle-based platforms, owing to their tunable physicochemical properties, surface modifiability, and multifunctionality, have emerged as promising tools for both diagnosis and therapy. A wide range of inorganic, organic, and carbon-based nanoparticles has demonstrated improved imaging contrast, enhanced biosensing capabilities, and potential for targeted, real-time diagnostics. On the therapeutic front, nanoparticles have shown the ability to concentrate therapeutic agents at or near injury sites; however, achieving precise delivery remains a major challenge. Indeed, nanoparticle-based therapies are still limited by off-target accumulation in peripheral organs, incomplete BBB penetration, and heterogeneous tissue distribution. Addressing these barriers requires optimizing particle size, surface charge, ligand conjugation, and degradability to improve site-specific targeting and minimize systemic toxicity. In this review, we examine major classes of nanoparticles, including organic, inorganic, carbon-based, and biologically derived nanocarriers, and discuss the key physicochemical properties governing their interactions with the central nervous system. We evaluate their applications in TBI diagnosis, neuroimaging, and therapy, emphasizing the design principles influencing blood-brain barrier penetration, targeting specificity, biodistribution, and clearance. We further assess emerging nanoparticle-based strategies to improve site-specific delivery and mitigate secondary brain injury, and highlight key translational challenges and future clinical directions. Continued research into biodegradable, biomimetic, and environmentally sustainable synthesis methods is essential to advancing nanoparticle design and ensuring their safe and effective integration into the clinical management of TBI.

Indexed as

Brain Injuries, TraumaticMultifunctional NanoparticlesNanoparticlesAnimalsBlood-Brain BarrierHumansblood-brain barrierexosomesnanoparticlesneuroimagingtargeted therapytraumatic brain injury

Identifiers

PMID41890658
PMCPMC13016135

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.